Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Tadsamillionaire who wrote (331)	7/3/1999 12:26:00 AM
From: sim1	Respond to of 422

NOT!

To: Tadsamillionaire who wrote (331)	7/10/1999 2:37:00 PM
From: Dataminer1	Read Replies (3) \| Respond to of 422

Pretty quiet here with BLUD at new highs. I guess everyone has moved to the Yahoo boards. The price action really looks good, and I'm hoping for a stellar earnings release. I planted a small seed way in the back of my garden with BLUD years ago when the ABS2000 was on the drawing board, and only wish I had accumulated more. I've gone from 5 to 15 and back a few times, hope this break-out is for real. I don't really have enough shares to spend much time on it, but maybe I'll post again when we get to 20. Good Luck, D1 stock-market-investing.com

To: Tadsamillionaire who wrote (331)	8/1/1999 11:13:00 PM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

R&A Fast Fact #7 - Instrument/Reagent Sales "Our sales estimates for the instrument line call for 120 units to be sold this year, more than doubling in FY2001 to 250. The mix is expected to be heavily weighted to the ABS2000. Reagent sales should be up by 40% in FY2000 based on our instrument forecast and increments from acquisitions, followed by a lesser gain in FY2001 as some cannibalization of manual reagent sales takes place. Gross margins should improve as the instrument/reagent trail component of sales increases, while SG&A can be leveraged as volume increases." Best O'Luck! Tom